CD8A and neoplasm: Surprisingly, a single intracranial injection of low-dose CNT-CpG removed intracranial GL261 gliomas in half of the tumour-bearing animals via activation of NK and CD8+ cells and protected the surviving mice from the recurrence of intracranial cancer [242].